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Background When collecting phenotypic data in clinics across the globe, the Type
1 Diabetes Genetics Consortium (T1DGC) used several techniques that ensured
consistency, completeness, and accuracy of the data.
Purpose Theaimofthisarticleistodescribetheproceduresusedforcollection,entry,
processing, and management of the phenotypic data in this international study.
Methods The T1DGC ensured the collection of high quality data using the
following procedures throughout the entire study period. The T1DGC used
centralized and localized training, required a pilot study, certified all data entry
personnel, created standardized data collection forms, reviewed a sample of form
sets quarterly throughout the duration of the study, and used a data entry system
that provided immediate feedback to those entering the data.
Results Due to the intensive procedures indeveloping the forms, the study was able to
uphold consistency among all clinics and minimal changes were required after
implementation of the forms. The train-the-trainer model was efficient and only a small
number of clinics had to repeat a pilot study. The study was able to maintain a low
percentageofmissingdata(<0.001%)andlowduplicatedataentryerrorrate(0.10%).
Conclusions It is critical to provide immediate follow-up in order to reinforce
training and ensure the quality of the data collected and entered. Clinical Trials
2010; 7: S46–S55. http://ctj.sagepub.com
Abbreviations
ASP affected sibling pair
ESPRIT Evaluation of Subcutaneous
Proleukin in a Randomized
International Trial
T1DGC Type 1 Diabetes Genetics
Consortium
Introduction
The Type 1 Diabetes Genetics Consortium (T1DGC)
recruited affected sibling pair (ASP) families, trio
families, cases, and controls in over 200 clinics
spanning four networks (Asia-Pacific, European,
North American, and United Kingdom) worldwide
[1]. A multi-level approach ensured that the quality
of the data remained high throughout the six years
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T1DGC and the number of participating clinics,
four Regional Network Centers were established
(Melbourne, Australia; Copenhagen, Denmark;
Seattle, Washington, USA; and Cambridge, United
Kingdom). Personnel at the Regional Network
Centers provided training for the clinic staff
within their own networks, performed site visits
as needed, reviewed completed forms, and entered
study data into a central database maintained at the
Coordinating Center. The Coordinating Center
(Winston-Salem, North Carolina, USA) was respon-
sible for overseeing all of the Regional Network
Centers. This model, similar to that in the
Evaluation of Subcutaneous Proleukin in a
Randomized International Trial (ESPRIT), allowed
for consistency across all clinics and reduced the
costs required for training [2]. As has become the
practice in multi-center studies, the T1DGC pri-
marily used the study website (https://t1dgc.org) to
allow consistent distribution of the study forms and
written procedure manuals to the Consortium
Members and data collection sites [2–4].
Extensive form review at every level (clinics,
laboratories, Network Centers, and Coordinating
Center), feedback through a query system, and the
use of dynamic reports allowed the study to iden-
tify and address data collection problems in a
timely manner. Using methods such as those used
in the T1DGC (i.e., providing immediate feedback
upon completion of data entry, requiring certifica-
tion for data entry personnel, and performing
duplicate data entry on a percentage of all forms),
other multi-center studies have been able to main-
tain a low data entry error rate [5–9].
Methods
To ensure that the data were collected consistently
among the 214 clinics around the globe, standard
data collection forms were used, rigorous form
review was completed in multiple locations, and a
data entry system was used to provide immediate
feedback regarding form completion and data entry
errors. Due to these intensive front-end quality
control mechanisms, the phenotypic data collected
by the T1DGC are exceptionally clean and com-
plete. A description of the form sets used in the
T1DGC is provided in Table 1.
Development and distribution of forms
To standardize T1DGC data collection, the same data
collection forms were used in every clinic throughout
thestudy.DataformswerecreatedattheCoordinating
Center with input and approval of various study
committees that were comprised of representatives
from each of the networks (e.g., the Phenotyping/
Recruitment Committee, the Network Coordinators
Committee, and the Steering Committee). Data forms
were pilot tested by the Network Coordinators at
several points during the development phase.
The informed consent was the only document
translated into the participant’s native language
[10]. Each clinic was required to have at least one
staff member who was fluent in both English and
the native language. All other forms were in
English, and clinic staff members were instructed
to read the questions to the participant in the
participant’s native language.
The number and length of the forms were kept
to a minimum to decrease participant burden. A
total of 17 forms were created for the typical family
data collection: eight forms exclusively for ASP
families; six forms for trio families; a layered
consent form [10]; and two blood collection forms
(original and re-collection). Six forms were created
for the case and control data collection: two
exclusively for cases; one exclusively for controls;
one consent record form used for both cases and
controls; and two blood collection forms, similar to
those used for the family collection. Form length
ranged from 2 to 10 pages and included up to 18
questions per form. Due to skip patterns, the
number of data fields on each form varied. The
number of data fields per form ranged from 6 to 84.
For each T1DGC family, one consent summary
form and one eligibility form was completed. The
consent summary form allowed the clinic staff to
track the type and date of consent for all family
members. One eligibility form was completed per
family and it assessed the eligibility of all key family
members. For each participant, an exam form and a
blood collection form were completed. To decrease
the amount of time the participant needed to be
present in the clinic, some forms could be com-
pleted from existing records or through a telephone
interview prior to the clinic visit.
As the T1DGC is primarily a family-based study,
questionswere phrasedsothattheycouldbeaskedof
either the participant or the parents (if young
children were participating). Questions were written
as if addressing the participant, with a variation of
eachquestioninparenthesesanditalics,forusewhen
questions were asked of the parent or guardian.
To emphasize responses that would make a
participant or family ineligible, check boxes were
shaded gray. While the use of skip patterns was
minimized, their use in the data forms could not be
eliminated. For example, the recruitment of parents
in ASP families was encouraged, but not required.
When the parents were participating, the family
history was captured on the parental exam form
and these questions were skipped on the proband
exam form. When the parents were not
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regarding his/her parent’s family history.
Answers to questions that would elicit different
responses due to international differences in
recording certain data (e.g., dates and body
weight) were anticipated. All dates were recorded
consistently as day, month, and year, with the
name of the month written out in its entirety. For
questions about weight and height, clinic staff
checked whether the answer was reported in
pounds or kilograms, and in inches or centimeters,
respectively.
‘Not applicable’ was added as an acceptable
response for some questions, based on network-
specific requirements. For example, ‘not applicable’
was recorded for date of birth in the United
Kingdom Network as these data cannot be collected
due to regulations in the United Kingdom. All
networks, with the exception of the North
American Network, selected ‘not applicable’ to the
question regarding whether the participant was of
Latino, Hispanic, or Spanish origin.
To provide easy access for all clinics across all
networks, for cost-efficiency, and for ease in future
changes to the forms, all forms were made available
through the T1DGC website to be printed as
needed by the clinic staff. Question-by-question
instructions for each form were included in the
manual of operations, which was also available on
the T1DGC website. The exception to clinic access
Table 1 Summary of T1DGC data collection forms
Form name Maximum number
of fields per form
Affected sibling pair form set: Required for core family completion
a
Eligibility form (completed by proband) OR eligibility form (completed by guardian) 50 or 54
Consent summary form 81
Layered informed consent (completed for proband AND affected sibling) 6
Exam form (proband) 84
Exam form (affected sibling) 46
Blood collection form (completed for proband AND affected sibling) 31
Additional affected sibling pair forms
b
Layered informed consent (completed for all additional family members) 6
Exam form (parent(s)) 58
Exam form (unaffected sibling(s)) 46
Exam form (additional affected sibling(s)) 46
Blood collection form(s) (completed for all additional family members) 31
Application(s) for additional affected sibling 31
Trio family form set: Required for core family completion
c
Pre-eligibility form
d 11
Eligibility form (completed by proband) OR eligibility form (completed by guardian) 30 or 33
Consent summary form 30
Layered informed consent (completed for all family members) 6
Exam form (proband) 61
Exam form (parent) (completed about father AND mother) 58
Blood collection form (completed for all family members) 31
Case participant form set: Required for participant completion
Eligibility form (completed by case) OR eligibility form (completed by guardian) 32 or 34
Consent record 15
Exam form (case) 83
Blood collection form 31
Control participant form set: Required for participant completion
Eligibility form (completed by control) OR eligibility form (completed by guardian) 35 or 38
Consent record 15
Blood collection form 31
aInclusion of the proband and one affected sibling is required for the core affected sibling pair family to be considered complete.
bInclusion of both biological parents, up to two unaffected siblings and an additional three affected siblings can be included in the
T1DGC affected sibling pair family.
cInclusion of the proband and both biological parents are required for the trio family to be considered complete.
dThe Pre-Eligibility Form is required in the North American Network. This form is not completed in any of the other networks.
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where the Network Center printed and distributed
form sets to the nurses who traveled among clinics
throughout a region.
Training and pilot study
Coordinating Center staff trained personnel at each
of the Network Centers in all aspects of data
collection and data entry. Each Network Center
was responsible for training study personnel at all
clinics within their network. All networks held at
least one central training session. For clinics joining
the T1DGC before or after the central training, or
when additional training was needed due to staff
turnover, logistic, or language issues, local training
was completed by Regional Network Center staff
members.
Each clinic was required to complete a pilot
study successfully on a mock family (usually vol-
unteer clinic staff) prior to initiating participant
recruitment. The pilot study covered all aspects of
enrolling participants, including: administering
individual consent; completing a full set of forms
for a family or participant; and collecting, process-
ing, and shipping blood samples. Pilot study forms
were sent to the Regional Network Center for entry
into the data entry system and all aspects of the
pilot study were reviewed and approved by the staff
of both the Regional Network Center and
Coordinating Center before certifying a clinic.
Feedback was provided to each clinic, noting
specific problems in form completion and/or
blood collection and shipping.
Form review
Clinic staff members were asked to review the data
collection forms for completion before the partic-
ipant(s) left the clinic and again before shipping to
the Regional Network Center for data entry. As
form sets were received, Regional Network Center
staff reviewed each form prior to data entry. Any
needed form corrections due to missing pages,
incorrect labeling, and other obvious errors were
communicated to the clinic staff through email
prior to data entry.
The Coordinating Center requested family form
sets from each network on a quarterly basis for
forms review and duplicate data entry. For each
clinic, the first two form sets were requested for
review; thereafter, a 5% sample of all forms com-
pleted during each quarter were re-entered and
reviewed by the Coordinating Center Project
Managers. Any form completion problems
discovered were sent to the Regional Network
Center Coordinator for communication to and
correction by the clinic staff. If the data entry
error rate was above 0.5% for any form, the
Network Center was required to compare the
entered forms with the paper forms, correct data
entry as needed, and re-save all forms of that
particular type for the affected quarter. Error rates
were calculated based on the total number of fields
per form set for each recruitment type.
Data entry system and rules
After clinics sent the data collection forms to one of
the four Regional Network Centers, the forms were
entered into the data entry system through the
T1DGC data entry website. This regional data entry
enabled the T1DGC to train and certify a small
number of individuals who became quite proficient
at data entry. This strategy also permitted tighter
security of phenotypic information by restricting
access to the data entry website to a small number
of trained staff. All data entry staff were required to
complete a data entry certification packet (consist-
ing of two complete form sets) prior to being
allowed to enter the data from T1DGC forms. Each
individual had to achieve 99.5% or better accuracy
on both form sets to achieve data entry
certification.
A directed flow of the data entry system required
that the informed consent forms be entered first,
followed by data from the eligibility forms. (See
Hall, et al. [10] for more details about what
information was entered from the informed con-
sent forms.) Only after entry of data from these
forms could the exam forms and blood collection
forms for the key participants (i.e., proband and
affected sibling in ASP families; all participants in
trio families; and cases and controls) be entered.
Following entry of data from these core forms, data
from the remaining exam and blood collection
forms could be entered for other participants in
families. Additionally, an interactive rules system
[11] provided immediate feedback to the data entry
personnel when attempting to add or modify data
records.
The interactive rule system allowed the data
entry system to display three types of messages to
the user if values were outside of a specified range
or fields were left missing (Figure 1). These mes-
sages conveyed the queries that should be verified
or corrected and helped to certify that the data
were entered with a high degree of accuracy.
Messages were displayed at the top of the data
entry screen and indicated by a colored dot beside
the response that was in question. ‘Informational’
messages (e.g., confirm ‘Don’t Know,’ number of
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blue dot, were used to confirm data entered that
were outside of what was normally expected for
fields that were not considered key information.
Informational messages did not require clinic ver-
ification, but were confirmed by the data entry staff
to check that the data were entered as recorded on
the form. ‘Warning’ messages, indicated by an
orange dot, allowed data entry staff to save the data
that they had entered, but these messages created
queries on dynamic reports and in the T1DGC
query system. Warning messages appeared for fields
that should be corrected or confirmed by the clinic
(e.g., date of birth not valid, participant diagnosed
outside of the expected age range). ‘Error’ messages,
indicated by a red dot, displayed when key data
entry fields were incorrect or missing, and the data
could not be saved in the database until these errors
were resolved (i.e., participant ID, clinic ID, sec-
ondary ID, date of exam, or date of blood collection
missing; or the indication that consent had been
obtained was not checked for the key participants
in the family). The number of fields that generated
error messages was kept to a minimum in order
to maximize the data saved at the time of initial
entry.
Dynamic reports and query system
A final check of data entry fields was provided by
using the online dynamic reports and the T1DGC
query system. The dynamic reports were produced
by an automated review of data that used cross-
form comparisons. These reports listed samples that
had not been shipped to the T1DGC laboratories,
any eligibility questions, and all other irregularities.
The interactive query system (Figure 2) was devel-
oped during the study to allow the Regional
Network Centers to review all the network’s queries
or to filter the list of queries by country, clinic, or
family. Queries displayed related to the messages
displayed at the time of data entry as well as cross-
form checks for consistency. Regional Network
Center staff members were able to confirm data
entered and abnormal values through the query
system (Figure 3). During the development of the
query system, the Network Coordinators and
Coordinating Center specified the queries that
could be verified at the Regional Network Center
level and those that required confirmation by the
clinic. Once Regional Network Center staff con-
firmed or corrected queries, the Coordinating
Center Project Managers reviewed each response
and either approved the response or requested
further correction or verification at the clinic level.
Dynamic reports were created showing various
levels of data and sample collection completeness
for families or cases and controls. ‘Known’ families
or cases and controls had some information in the
T1DGC system. ‘Eligible’ families or cases and
controls met the eligibility criteria, but did not
have all exam information and blood samples
entered into the system. ‘Completed core’ families
Figure 1 Error, warning, and informational messages in the T1DGC data entry system.
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complete, but outstanding issues remained for the
other family members. ‘Completed’ families or
cases and controls had all forms entered and all
samples received at the laboratories; however,
outstanding queries remained. ‘Completed close-
out’ families or cases and controls had all informa-
tion in the system, all samples received at the
laboratories, and no remaining queries.
When a clinic had concluded recruitment and
was in the process of being closed, the Regional
Network Center Coordinator and Coordinating
Center Project Manager checked all reports and
the T1DGC query system to verify that no
remaining outstanding issues or queries remained.
For a clinic to be closed, all families, cases,
and controls recruited by that clinic must be
identified in the dynamic reports as ‘Completed
close-out.’
Results
Development and distribution of forms
By having the staff from the Regional Network
Centers and Coordinating Center involved in the
initial creation, development, and testing of the
data collection forms, the forms required very few
revisions sothatthe datawere collectedconsistently
throughout the six-year recruitment period of the
project. The majority of revisions to forms after data
collectionbeganaffectedonlythewording;onlyone
change involved adding a variable to the database.
Figure 3 T1DGC interactive query system, examples of queries.
Figure 2 T1DGC interactive query system.
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circumstances, but were not part of the standard
form set.
Several of the forms required skip patterns to
obtain the needed information; these patterns
often created problems when the pattern was not
followed at clinics and the forms had to be sent
back to the clinic for correction. Additionally, one
unanticipated complication that developed was
when all members of a participating family did
not attend the same clinic visit. When the initial
participant thought his or her parents were going to
participate, the family history section was skipped
on the initial form. If the parents subsequently
decided not to participate or could not be reached,
data fields in that section were missing. To obtain
this critical study information, it was decided that if
the parents were not present at the initial clinic
visit, the family history should be collected and
recorded on the proband exam form. If the parent
did participate later, the information collected from
the parent (and recorded on the parental exam
form) was deemed more accurate and was used in
place of the information collected on the proband
exam form.
Training and pilot study
The train-the-trainer model used in the T1DGC
allowed the Coordinating Center and Network
Centers to modify the training to meet each
network or clinic’s specific needs. When the
Network Center staff performed local training,
often they would remain at the clinic and oversee
the completion of the pilot study. Completion of
the initial pilot studies also allowed the T1DGC to
determine how long it would take for samples to
arrive at the network laboratories and shipping
days could be modified as needed to verify that
samples could be received within 24 to 48h of
blood collection. While most clinics were certified
to begin data collection after a single pilot study,
six (4.3%) clinics with serious errors were required
to complete a second pilot study.
Form review
As of July 4, 2009, data from a total of 50,236 forms
had been entered through the T1DGC data entry
system (Table 2). Due to the rigorous form review
practices and the interactive ILOG JRules employed
in the data entry system, the number of missing
data fields was less than 0.001% (Table 3) for more
than 30 million data fields.
The overall time from recruitment to data entry
was roughly 50 days for ASP and trio family forms,
although this varied by network. The overall time
from recruitment to data entry was lower for the
case and control forms (Table 4).
From the form review completed at the
Coordinating Center, a few key issues were identi-
fied that appeared consistently across all the net-
works; these were communicated to the Network
Coordinators so that they could work with the
clinic staff. The Regional Network Coordinators
also were encouraged to highlight these problems
in subsequent training of personnel at new clinics
to prevent their continuing occurrence. The fre-
quency of these problems decreased in clinics
where the study personnel were trained later in
the study. The most common problems identified
included not following skip patterns and not
Table 2 Summary of data forms entered for completed families and participants, by network and overall, T1DGC, July 4, 2009
Network Total (N) ASP forms
(N families)
Total (N) trio forms
(N families)
Total (N) case forms
(N cases)
Total (N) control forms
(N controls)
Asia-Pacific 4725 (324) 2226 (265) 16 (16) 6 (17)
European 16,920 (1211) 115 (10) 14 (13) 6 (9)
North American 16,959 (1143) 2237 (186) 1907 (519) 2011 (692)
United Kingdom 2394 (163) N/A N/A N/A
Overall 40,998 (2841) 5278 (461) 1937 (548) 2023 (718)
Table 3 Number of missing data fields
a, by network and
overall, T1DGC, July 4, 2009
Network ASP
forms
Trio
forms
Case
forms
Control
forms
All
forms
Asia-Pacific 15 6 0 0 21
European 13 2 0 0 15
North American 198 9 88 82 377
United Kingdom 16 N/A N/A N/A 16
Overall
b 242 17 88 82 429
aThepercentageofmissingdatafieldswaslessthan0.001%foreach
form type.
bThe total number of fields for each type of data form set was:
affected sibling pair (ASP)¼27,519,470; trio¼2,103,645;
case¼395,760; control¼147,679; and overall¼30,166,554.
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the forms.
Very early in the study, the Coordinating Center
discovered deviations from the study protocol at
one network when reviewing the data collection
forms. It was found that the data in the data entry
system did not match the source document. When
this discrepancy was discovered, all data for this
network were marked as invalid in the data entry
system and the Regional Network Center data entry
staff re-entered data from all forms exactly as they
had been recorded and requested corrections from
the clinics when appropriate. Forms review follow-
ing re-entry confirmed that the network center staff
had entered the data correctly.
Data entry system and rules
The Coordinating Center certified 22 Network
Center staff members in data entry. Two staff
members were required to complete a second
certification due to an accuracy rate lower than
99.5%.
As noted earlier, the Coordinating Center staff
entered data from a 5% sample of data collection
forms from each network every quarter. The dupli-
cate data entry system allowed for a comparison
of these data to the original data entered at
the Regional Network Centers; an overall and
form-specific entry error rate was calculated.
Whenever the data entry error rate was higher
than 0.5% on any particular form, the Regional
Network Center staff compared all paper forms
of that type from that quarter with the study
database. In only 27 instances throughout the
duration of the study and across all networks was
this type of review required. In the vast majority
(N¼384), no data entry errors were found. The
overall data entry error rate throughout the study
was 0.1% (Table 5).
Dynamic reports and query system
The dynamic reports were created with the input of
the Regional Network Centers; however, the
T1DGC query system was introduced after several
of the Regional Network Centers had procedures in
place for addressing queries. Because of the delay in
implementation of the T1DGC query system, there
were a large number of queries that had to be
resolved. In order to identify the queries that were
more critical, the Coordinating Center Project
Managers and Regional Network Coordinators
reviewed all queries and identified the questioned
items that could be verified and those that had to
be corrected by the clinic personnel. This review
decreased the number of queries sent to the clinics
to a manageable number, without jeopardizing the
quality of the data.
Table 5 Data entry error rates per data entry field (%) by quarter and overall, T1DGC, July 4, 2009
Year 1 2 3 4 5 Overall
Quarter 4123412341234123
Network
Asia-Pacific 0.61 0.11 0.05 0.03 0.06 0.00 0.05 0.33 0.07 0.15 0.03 0.14 0.03 0.00 0.00 0.09 0.10
European 0.02 0.04 0.08 0.03 0.00 0.11 0.04 0.08 0.06 0.11 0.02 0.04 0.07 0.03 0.42 0.08 0.06
North American 0.07 0.06 0.03 0.20 0.11 0.17 0.11 0.05 0.17 0.07 0.13 0.15 0.15 0.03 0.03 0.23 0.11
United Kingdom 0.14 0.31 0.82 0.11 0.02 0.08 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.16
Overall 0.19 0.11 0.11 0.09 0.05 0.11 0.07 0.11 0.11 0.10 0.09 0.11 0.12 0.03 0.18 0.13 0.10
Table 4 Summary statistics for time (days) from data collection to data entry, by network and overall, T1DGC, July 4, 2009
Network ASP forms
mean SD
(median, range)
Trio forms
mean SD
(median, range)
Case forms
mean SD
(median, range)
Control forms
mean SD
(median, range)
Asia-Pacific 43.9 82.8 (21,932) 43.4 63.4 (27, 1181) 15.8 2.2 (15.5, 6) 14.5 1.6 (14.5, 3)
European 76.5 125.4 (40, 1569) 170.4 139.8 (161, 614) 433.1 131.6 (455, 565) 456.0 0.0 (456, 0)
North American 27.6 55.8 (11, 1100) 50.5 86.6 (15, 635) 20.5 30.0 (11, 242) 19.9 34.2 (11, 357)
United Kingdom 47.0 59.4 (28, 696) N/A N/A N/A
Overall 50.7 96.4 (22, 1570) 49.6 79.0 (24, 1186) 23.7 48.2 (11, 721) 21.2 41.6 (11, 456)
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To ensure that the quality of phenotypic data was
consistent and accurate across multiple clinics from
countries around the world, an effective and effi-
cient plan for data collection, data entry, and data
verification had to be in place. It was critical to have
input from representatives from each participating
network to assure consideration of cultural factors.
Due to time constraints and staggered entry of
clinics into the study, it was not possible to obtain
feedback from every clinic before data collection
began. However, changes to the plan were made
based on feedback from members of the Network
Centers, Steering Committee, and Phenotyping/
Recruitment Committee. Feedback from the initial
clinics and the Regional Network Centers
allowed the study to identify issues with forms
completion and to revise the forms prior to their
implementation.
Although the number of forms was kept to a
minimum, clinic staff still found the completion of
a form set to be a time-consuming task. The North
American Network consistently had a lower time
from collection to entry due to the shorter distance
from the clinics to the Network Center and the use
of courier services (as opposed to regular post) to
ship data collection forms. Some delays were due to
missing key information; forms could not be
entered until this information was provided and
sent to the Regional Network Centers.
Through regular site visits to the Regional
Network Centers and form review, the
Coordinating Center was able to monitor the
quality and accuracy of the study data, ensuring
that corrections were made when needed by using
appropriate procedures. The low data entry error
rate can be attributed to the rigorous form review
and the implementation of the ILOG JRules system
that flagged potential problems early during the
data entry process.
The query system was not developed early
enough in the data collection process to permit
standardizing the procedures for handling queries
across the networks. By requiring verification
through the T1DGC query system after network-
specific procedures had been established, the query
system was viewed more as a burden than as a
useful tool. To decrease the burden, the T1DGC
identified specific critical queries that required
verification and stopped requiring verification of
noncritical fields. Implementation of procedures
designed to assure the consistency, completeness,
and accuracy of the data should occur early in any
study and be uniform across all clinics.
The distribution of tasks between the
Coordinating Center, Network Centers, and clinics
allowed each T1DGC member to contribute to the
collection of high quality data. Due to the stan-
dardization of data collection and extensive quality
control checks, the phenotypic data collected
by the T1DGC are accurate and complete. The
high quality of the T1DGC phenotypic database
will permit reliable interpretation of other study
findings and provide the basis for meaningful
publications well into the future.
Conclusions and recommendations
Conclusions and recommendations from the
T1DGC apply to many multi-center studies. Close,
immediate follow-up regarding performance is
important to clinics. Site visits should be conducted
early in the study in order to identify and rectify
any problems quickly and efficiently. It is critical
to receive input from all networks in order to verify
that the forms are sensitive to social and cultural
influences and that the data are collected
accurately.
The data cleaning and verification process
should be developed in conjunction with the data
collection forms. Centralized data entry allows a
minimal number of people to be trained and
monitored and can reduce data entry error rates.
By employing extensive checks through the
data entry system that provide instant feedback,
and using manual review of forms, the staff of the
clinics and Regional Network Centers can receive
feedback that reinforces training and assures the
quality of the data collected and entered.
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